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The interplay between mucosal immune responses to natural exposure to mutans streptococci and the incorpo-
ration and accumulation of these cariogenic microorganisms in oral biofilms is unclear. An initial approach to
explore this question would be to assess the native secretory immunity emerging as a consequence of Streptococcus
mutans infection. To this end, we analyzed salivary immunoglobulin A (IgA) antibody to mutans streptococcal
glucosyltransferase (Gtf) and glucan binding protein B (GbpB) and to domains associated with enzyme function
and major histocompatibility complex (MHC) class II binding in two experiments. Salivas were collected from
approximately 45-day-old Sprague-Dawley rats, which were then infected with S. mutans SJ32. Infection was verified
and allowed to continue for 2 to 2.5 months. Salivas were again collected following the infection period. Pre- and
postinfection salivas were then analyzed for IgA antibody activity using peptide- or protein-coated microsphere
Luminex technology. S. mutans infection induced significant levels of salivary IgA antibody to Gtf (P < 0.002) and
GbpB (P < 0.001) in both experiments, although the levels were usually far lower than the levels achieved when
mucosal immunization is used. Significantly (P < 0.035 to P < 0.001) elevated levels of postinfection salivary IgA
antibody to 6/10 Gtf peptides associated with either enzyme function or MHC binding were detected. The postin-
fection levels of antibody to two GbpB peptides in the N-terminal region of the six GbpB peptides assayed were also
elevated (P < 0.031 and P < 0.001). Interestingly, the patterns of the rodent response to GbpB peptides were similar
to the patterns seen in salivas from young children during their initial exposure to S. mutans. Thus, the presence of
a detectable postinfection salivary IgA response to mutans streptococcal virulence-associated components, coupled
with the correspondence between rat and human mucosal immune responsiveness to naturally presented Gtf and
GbpB epitopes, suggests that the rat may be a useful model for defining mucosal responses that could be expected
in humans. Under controlled infection conditions, such a model could prove to be helpful for unraveling relation-
ships between the host response and oral biofilm development.
Initial colonization of the human oral cavity by commensal
bacteria, such as Streptococcus mitis (28, 33), is quickly fol-
lowed by secretory immune responses to these microorgan-
isms, which can be detected in saliva (6, 35). Significant het-
erogeneity is observed in these early responses (35). As
additional oral habitats develop, colonization by a broader
spectrum of commensal microorganisms takes place. Each spe-
cies is likely to induce unique secretory immune responses, as
well as enhance the response to cross-reacting epitopes already
present. Mutans streptococci, which are strongly associated
with dental caries (14), usually colonize children during the
second year of life, when oral habitats are more complex (3,
19). Exposure to these cariogenic streptococci also results in a
detectable, although varied, set of secretory immune responses
to several of the mutans streptococcal components associated
with successful acquisition (34).
The significance of these so-called natural secretory immune
responses to members of the oral biofilm is unclear. Cole and
coworkers (6) have suggested that a portion of the response is
polyclonal and of lower affinity and has an innate immunity-
like rapid response role. It is also likely that adaptive, higher-
affinity secretory immune responses are also generated during
colonization, especially at the outset of colonization. The va-
riety of specificities seen in secretory (salivary) immunoglobu-
lin A (IgA) responses to earlier-colonizing oral streptococci
(e.g., S. mitis and Streptococcus salivarius) and later-colonizing
oral streptococci (e.g., Streptococcus mutans) supports this con-
cept. Some of the natural higher-affinity responses might also
modulate the success or duration of colonization. For example,
recent evidence suggests that early formation of salivary IgA an-
tibody to S. mutans glucan binding protein B (GbpB) (2, 18) may
delay colonization of young children who are being heavily chal-
lenged with this cariogenic streptococcus (25, 26). The effect of
salivary IgA antibody on S. mutans acquisition is compatible with
observations indicating that experimental provision of antibody to
mutans streptococcal virulence components by either active or
passive immunization can provide protective immunity to exper-
imental infection with S. mutans or Streptococcus sobrinus (for
reviews, see references 12 and 31).
Rats have frequently been used to explore the effect of
increasing the secretory (salivary) immune response by immu-
nization with a variety of putative virulence epitopes on sub-
sequent oral disease, especially dental caries (31). However,
the use of this model to study the effect which salivary IgA
antibody, naturally induced by infection, could have on the
success or extent of colonization with S. mutans is relatively
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unexplored. This approach should help us to understand the
role of natural immunity in acquisition of the cariogenic strep-
tococci in the human oral biofilm. In order to apply the model
in this way, the characteristics of natural salivary IgA immune
responses to components associated with adhesion or accumu-
lation of S. mutans following infection alone would be re-
quired. In this regard one could follow development of salivary
IgA antibody to glucosyltransferases (Gtf) and glucan binding
protein B (GbpB), as well as intrinsic peptides with putative
functional or major histocompatibility complex (MHC) bind-
ing roles, which have also been shown to elicit significant im-
mune responses and, in some cases, protective immunity in
experimental models. Such epitopes include several sequen-
tially distinct residues in the N-terminal half of glucosyltrans-
ferase which are associated with its catalytic activity (8, 9, 16,
22–24, 42). Also included would be natural immune responses
to regions associated with the ability of Gtf to bind glucan
through a series of repeating sequences in the C-terminal third
of the molecule (1, 17, 43). Although functional domains in S.
mutans GbpB have not yet been identified (20), several peptide
sequences in the GbpB structure (21) have potential for MHC
binding.
Thus, the purpose of the present investigation was to study
the attributes of the natural secretory immune response to
components of S. mutans important to its colonization by anal-
ysis of the presence and patterns of salivary IgA immune re-
sponses to Gtf and GbpB and to 16 associated peptides which
are related either to function or to MHC binding after exper-
imental challenge of rats with S. mutans.
MATERIALS AND METHODS
Animals for infection experiments. Pathogen-free Sprague-Dawley CD strain
rats (Kingston facility, Charles River) were used in the infection studies. Prior to
infection, all rats were initially housed in single-animal cages and were fed
pelleted laboratory chow (Harlan Teklad Corp.). All rats in the infection exper-
iments had previously served as sham-immunized controls for immunization
experiments. Before infection, each rat in all experiments received two subcuta-
neous injections in the vicinity of the salivary gland of phosphate-buffered saline
when it was approximately 24 days old (in complete Freund adjuvant [Difco
Laboratories, Detroit, MI]) and when it was 45 days old (in incomplete Freund
adjuvant [Difco]). Infection with S. mutans was then initiated approximately 3 to
5 days after the second sham immunization at an age when all rat molars were
erupted.
Rat infection. All rats in the infection studies were challenged with S. mutans
strain SJ32 when they were 48 to 50 days old. Rats were placed in tubs (six
rats/tub), given cariogenic diet 2000 (56% confectioner’s sugar), and orally in-
fected with 108 streptomycin-resistant S. mutans SJ32 cells for three consecutive
days. Rats were again housed in single-animal cages after the infection protocol
was completed and given diet 2000 for the duration of the experiment. Infection
was verified for all rats after systematic swabbing of rat molars and plating on
mitis salivarius agar and mitis salivarius agar with streptomycin as previously
described (41). In experiment 1, 74 days after infectious challenge, S. mutans
accounted for 22 to 93% (median, 39%) of the total streptococcal flora. In
experiment 2, 62 days after infectious challenge, S. mutans accounted for 30 to
88% (median, 57%) of the total streptococcal flora. Postinfection salivas were
collected 65 (experiment 2) or 79 (experiment 1) days after the initial challenge
with S. mutans.
Group comparisons. Pre- and postinfection salivas from experiment 1 (n  11)
and experiment 2 (n  11) were used for measurement of salivary IgA antibody
to Gtf, Gtf peptides, and GbpB. Salivas were also analyzed for salivary IgA
antibody to GbpB peptides. Since many of the salivas from experiment 1 and all
salivas from experiment 2 were depleted, 13 pre- and postinfection salivas from
two additional experiments (rats infected on day 50 and salivas collected 52 to 59
days later) in which similar sham immunization and S. mutans infection protocols
were used were screened together with five pre- and postinfection salivas from
experiment 1 for antibody to GbpB peptides (n  18).
Animals for the immunization experiment. To compare the secretory (sali-
vary) immune response to S. mutans infection with mucosal induction of salivary
IgA antibody by immunization, salivas from the following immunization exper-
iment were assayed for antibody to Gtf. S. sobrinus Gtf antigen was incorporated
into a poly(D,L-lactide-co-glycolide) (PLGA)-based (ratio of lactide to glycolide,
75:25) biodegradable carrier copolymer (Boehringer Ingelheim Chemicals, Inc.)
using 1% gelatin as a bioadhesive agent, as previously described (36). The dose
used for this immunization experiment released approximately 10 g of Gtf.
Alternatively, 50 g of S. sobrinus Gtf was mixed with aluminum phosphate.
Forty-day-old Sprague-Dawley rats were inoculated intranasally three times at
1-week intervals with Gtf-PLGA microparticles (n  8) or with Gtf mixed with
aluminum phosphate (n  8) or were sham immunized with empty PLGA
microparticles (n  8). Salivas from all 24 rats were collected 15 days after the
last intranasal inoculation, clarified, and stored frozen until antibody analysis.
Saliva collection. Saliva samples were collected from all rats in the infection
experiments when the rats were approximately 45 days old (preinfection saliva)
and after approximately 2 to 2.5 months of infection with S. mutans SJ32. To
collect saliva, rats were first momentarily anesthetized with a gas mixture con-
taining 50% carbon dioxide and 50% oxygen and then anesthetized by intraper-
itoneal injection of a mixture (0.65 ml/kg) containing 3 parts ketamine (Ketaset;
100 mg/ml; Fort Dodge Lab, Ft. Dodge, IA) and seven parts xylazine (Rompun;
20 mg/ml; Bayer Corp., Shawnee Mission, KS). Saliva secretion was stimulated by
subcutaneous injection of 0.6 ml carbachol (0.1 mg/ml in saline; Sigma Chemical
Co., St. Louis, MO) per kg of rat. After saliva collection, rats were awakened by
subcutaneous injection of 0.1 ml/kg of atropine sulfate (0.4 mg/ml; American
Pharmaceutical Partners, Inc., Los Angeles, CA) and then yohimbine (yobine;
2.0 mg/ml; Lloyd Laboratories, Shenandoah, IA) using a volume that was 1.4
times the volume used for anesthesia. Clarified saliva was stored at 70°C.
Protein preparation. S. mutans strain SJ23 GbpB and S. sobrinus strain 6715
Gtf were prepared as previously described (32, 40). The S. mutans GbpB was
homogeneous in Western blots. The S. sobrinus Gtf preparation contained a
mixture of Gtf isotypes, approximately 30% of which was Gtf-I, which shares
80% homology with S. mutans GtfB and GtfC. S. sobrinus Gtf-S isotypes
comprised the balance of the Gtf preparation.
Peptides. Peptide constructs were synthesized by AnaSpec, San Jose, CA, as
multiple antigenic peptides using the stepwise solid-phase method of Merrifield
with a core matrix of lysines, which yielded macromolecules with four identical
peptides, as previously described (39). Six monoepitopic peptide construct se-
quences (QGQ, VAR, SYI, QAA, ANY, and SIG) were based on predicted
human MHC class II epitopes (11) that were in the GbpB sequence, using the
ProPred algorithm (30). Three monoepitopic peptide construct sequences (Pep
7, Pep 11, and Pep 16) were based on predicted MHC class II epitopes that were
in the Gtf sequence, using the ProPred algorithm. Five monoepitopic peptide
construct sequences (GGY, CAT, HDS, LVK, and VMAD) were based on Gtf
sequences associated with putative catalytic interactions (8, 9, 22–24, 42). Two
monoepitopic peptide construct sequences (GLB and GLU) were based on Gtf
sequences associated with putative glucan binding domains in the C-terminal
third of the Gtf protein (1, 17, 43). Of further interest, several of these peptides
(SYI, GGY, CAT, GLU, and Pep 11) have been shown to induce protective
immune responses to the cariogenic effects of S. mutans and/or S. sobrinus
infection (7, 31, 38, 41). The Gtf/GbpB locations and sequences of the peptides
are shown in Fig. 1 and Table 1.
IgA antibody measurement. Salivas were diluted 1:16 in PBS-BN (phosphate-
buffered saline (Sigma Chemical), 1% bovine serum albumin [BSA] (Sigma
Chemical), 0.05% sodium azide [pH 7.4]) and then filtered with 0.22-m cen-
trifuge tube filters (Spin-X; CoStar). Salivary IgA antibody reactivities with Gtf
or GbpB or with peptides derived from these proteins were tested using a
particle-based multiplex fluorescent immunoassay (Luminex). Fluorescently
tagged microspheres with different fluorescent signatures were coated with Gtf,
GbpB, or 1 of 16 protein-derived peptides. Protein and peptide antigens were
covalently attached to these beads via their amines using the “protein coupling
protocol” (www.luminexcorp.com/support/protocols/protein.html). Optimal
coating of 3.75  106 beads required 7.5 g of protein and 3.75 g (SIG peptide),
7.5 g, or 37.5 g (HDS and LVK) of peptide. However, at this bead concen-
tration 190 g of the VMAD peptide and 260 g of the ANY peptide were used,
and 600 g of the QAA peptide coated beads at less than saturation. Each saliva
assay well contained 2,500 beads with each antigen. The mixtures used for assays
contained (i) a combination of all GbpB peptide-coated microspheres, (ii) a
combination of all Gtf peptide-coated microspheres, or (iii) native Gtf protein-
and GbpB protein-coated microspheres. To avoid cross-reactions between anti-
body and similar peptide epitopes, GLU and GLB peptide-coated beads were
always tested in separate wells, as were LVK and VMAD peptide-coated beads.
Uncoated microspheres were added to each mixture as controls. Bead mixtures
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(50 l) were added to wells in 1.2-m-pore-size filter plates (Millipore Corp.,
Bedford, MA). Microspheres were then washed twice with PBS-BN under a
vacuum and resuspended in 50 l of the same buffer. Fifty microliters of each
diluted saliva sample (diluted 1:16 in PBS-BN) was then added and incubated at
37°C with shaking for 120 min. After the buffer was drained under a vacuum,
microspheres were incubated with a 1:250 solution of mouse monoclonal anti-rat
IgA (MARA-2 clone; Accurate Chem Scientific Corp.) in PBS-BN for 30 min at
37°C. Microspheres were then incubated with a 1:250 solution of R-phyco-
erythrin-conjugated goat anti-mouse IgG (Invitrogen) for 30 min at 37°C. All
incubations were performed in the dark. After washing, the samples were resus-
pended in PBS-BN and read with a Luminex 100 analyzer to obtain a median
fluorescence intensity (FI). The appropriate value was subtracted to account for
the background in the wells without saliva for each antigen. The median coeffi-
cient of variation for positive replicates was 14.8%.
The total salivary IgA relative to the IgA in a standard rat saliva was measured
in a separate plate by incubating a 1/2,000 dilution of saliva with beads coated
with affinity-purified goat antibody to rat IgA (United States Biological, Swamp-
scott, MA). The reaction was detected with monoclonal mouse anti-rat IgA and
then with phycoerythrin-conjugated goat anti-mouse IgG, as described above.
Individual salivary postinfection IgA antibody FIs were considered positive if
they were greater than the mean preinfection FI plus 2 standard deviations (SD)
for the group, when assays were performed using the corresponding peptide- or
protein-coated beads. The results are expressed as the median FI divided by the
total IgA concentration.
Statistical analysis. The statistical significance of differences between the
increase in postinfection levels for groups of salivas assayed with spheres coated
with Gtf/GbpB epitopes and the corresponding increases for salivas tested with
the spheres coated with BSA was analyzed by one-way analysis of variance
(ANOVA), followed by the Tukey pairwise multiple-comparison test, in which
data were normally distributed. Alternatively, data were analyzed by Kruskal-
Wallis one-way ANOVA on ranks, followed by Dunn’s multiple-comparison
procedure when nonparametric distributions were encountered.
RESULTS
Salivary IgA antibody reactivity with Gtf following S. mutans
infection. Salivas were collected from 22 44- to 46-day-old rats
(experiments 1 and 2) before infection with S. mutans, and
then salivas were collected again following an approximately
2-month infection period. Salivary IgA antibody to Gtf was
measured in pre- and postinfection salivas, after which the
antibody activity (expressed as FI) was normalized for individ-
ual salivary IgA concentrations. As shown in Table 2, the mean
increase in IgA antibody activity with Gtf after 2 months of
exposure to S. mutans was more than 10-fold (P  0.002) in
both experiments. Figure 2 shows the increases in salivary IgA
antibody (FI/IgA) to Gtf for both experiments. Appreciable
variation in the ability of rats to mount a mucosal immune
FIG. 1. Location of peptides in the sequences of Gtf and GbpB. Putative functional domains of Gtf are indicated above the Gtf diagram.
TABLE 1. Peptides used for detection of salivary IgA antibody
Source Peptide Sequence Putative importance Reference(s)
S. mutans GbpB QGQ 52-KHKLITIQGQVSALQTQQAG-71 MHC class II binding peptide 38
VAR 92-TLSSKIVARNESLKQQARSAQ-111 MHC class II binding peptide 38
SYI 113-KSNAATSYINAIINSKSVSD-132 MHC class II binding peptide 38
QAA 252-QAAQAQVAANNNTQATDASDQ-270 MHC class II binding peptide 38
ANY 390-AYVTGVQGGQIQVQEANYAG-409 MHC class II binding peptide 38
SIG 412-SIGNYRGWFNPGSVSYIYPN-431 MHC class II binding peptide 38
S. mutans GtfBa GGY 402-GGYEFLLANDVDNSNPVVQ-418 Catalytically implicated residues 9
CAT 442-DANFDSIRVDAVDNVDADLLQ-461 Catalytically implicated residues 24
Pep 7 505-LMNMDNKFRLSMLWSLAKPT-525 MHC class II binding peptide 7
HDS 552-VPSYSFIRAHDSEVQDLIA-570 Catalytically implicated residue 8, 29, 42
Pep 11 853-VVIANNVDKFVSWGITDFEM-872 MHC class II binding peptide 7
LVK 911-LVKAIKALHSKGIKVMADW-937 Catalytically implicated residues 22
VMAD 925-VMADWVPDQMYAFPEKELL-943 Catalytically implicated residues 22
GLB 1235-TGARTINGQLLYFRANGVQVKG-1257 Glucan-binding domain 1, 17, 39, 43
GLU 1297-TGAQTIKGQKLYFKANGQQVKG-1318 Glucan-binding domain 1, 17, 39, 43
Pep 16b 1364-SGALRFYNLKGQLVTGSGWY-1383 MHC class II binding peptide 1, 17, 39, 43
a Gtf peptide sequence numbers are shown for S. mutans GtfB. Residues which are different in S. sobrinus Gtf-I are indicated by bold type.
b Peptide found only in S. sobrinus Gtf-I. Residues which are complementary to S. mutans GtfB residues are underlined. Residues which are different in GtfB and
Gtf-I are indicated by bold type.
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response to infection was observed. However, 7/11 salivas in
experiment 1 and 10/11 salivas in experiment 2 contained levels
of IgA antibody to Gtf that were greater than the mean plus 2
SD of the reactivity of all salivas tested against BSA. Thus,
infection was usually sufficient to induce a detectable mucosal
immune response to Gtf under the infection and analysis con-
ditions used.
Salivary IgA antibody reactivity with GbpB following S. mu-
tans infection. Salivary IgA antibody to GbpB/IgA was also
measured in the pre- and postinfection salivas in experiments
1 and 2. Table 2 shows that despite appreciable variation in
FI/IgA antibody levels among rats, significant (P  0.001)
increases in IgA antibody activity for GbpB were observed
after 2 months of exposure to S. mutans. Figure 3 shows the
increases in the levels of salivary IgA antibody (FI/IgA) to
GbpB for each saliva in both experiments. More than one-half
of the postinfection salivas (6/11 salivas in experiment 1 and
8/11 salivas in experiment 2) contained levels of IgA antibody
to GbpB that were greater than the mean plus 2 SD for the
reactivity of all salivas tested against BSA. Thus, infection was
also sufficient to induce a detectable mucosal immune response
to GbpB in many animals. Interestingly, 59% of the salivas had
significant postinfection responses to both Gtf and GbpB.
Salivary IgA antibody reactivity with Gtf- or GbpB-derived
peptides following infection. (i) Gtf peptides. Since infection
with S. mutans resulted in the appearance of salivary IgA
antibody to Gtf and to GbpB in many animals, it was of
interest to identify the molecular epitopes to which natural
mucosal IgA antibodies were induced. To this end, the pre-
and postinfection salivas of all rats in experiments 1 and 2
were assayed for IgA antibody activity against a panel of 10
Gtf-derived peptides (Table 1 and Fig. 1) that had been
associated either with putative regions containing functional
activity or with peptides that had MHC class II binding
activity. Several of these peptides (GGY, CAT, Pep 11, and
GLU) previously had been shown to induce a protective
immune response to infection with cariogenic mutans strep-
TABLE 2. IgA antibody in salivas obtained before and after S. mutans infection















1 11 Preinfection 22.4  30.8 6.1  2.4
Postinfection 258.4  431.3 0.002 24.6  37.9 0.001 79
2 11 Preinfection 2.6  6.9 11.1  7.3
Postinfection 53.8  65.1 0.001 23.9  8.1 0.001 66
FIG. 2. Salivary IgA antibody reactivity to Gtf in rats whose salivas
were taken before infection and after 79 days (experiment 1) or 66 days
(experiment 2) of infection with S. mutans SJ32. The results are ex-
pressed as increases in postinfection salivary IgA antibody activity
compared with preinfection salivary IgA antibody activity, measured as
the Luminex FI for reactions of salivas with Gtf- or BSA (control)-
coated microspheres divided by the IgA concentration of the saliva.
The cross-hatched bars indicate the mean plus 2 SD for the BSA
control run in duplicate for each saliva.
FIG. 3. Salivary IgA antibody reactivity with GbpB in rats whose
salivas were taken before infection and after 79 days (experiment 1) or
66 days (experiment 2) of infection with S. mutans SJ32. The results
are expressed as the increases in postinfection salivary IgA antibody
activity compared with preinfection salivary IgA antibody activity,
measured as the Luminex FI for reaction of salivas with GbpB- or BSA
(control)-coated microspheres, divided by the IgA concentration of the
saliva. The cross-hatched bar indicates the mean plus 2 SD for the BSA
control run in duplicate for each saliva.
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tococci (7, 31, 41). Figure 4 shows the median postinfection
increases in the FI/IgA antibody value for each of the pep-
tides assayed with all 22 salivas from both experiments. This
group of salivas showed significant postinfection increases in
FI/IgA antibody levels when the reactivities with the CAT
and HDS peptides from the N-terminal third of the Gtf
molecule, the VMAD peptide from the central region, and
three peptides from the glucan-binding C-terminal third of
the molecule (GLB, GLU, and Pep 16) were compared with
the change in reactivity when salivas were tested against
BSA. The HDS peptide (residues 549 to 567), which con-
tains at least one residue implicated in catalysis (42), and
the two similar peptides derived from the putative glucan
binding domain (GLB and GLU) exhibited the highest
mean and median increases. Significant postinfection in-
creases in the antibody activities of the saliva groups were
not observed with several peptides (GGY, Pep 7, Pep 11,
and LVK), although occasional salivas did exhibit apparent
increases in responses to these peptides after infection.
Thus, following infection “natural” IgA antibody responses
to Gtf epitopes that are associated with the catalytic and
glucan binding activities of the enzyme can be observed.
(ii) GbpB peptides. Eighteen pre- and postinfection saliva
pairs were assayed for IgA antibody activity against a panel of
six GbpB-derived peptides (Table 1 and Fig. 1) that had been
associated with peptides that had MHC class II binding activ-
ity. Figure 5 shows the median postinfection increases in FI/
IgA salivary antibody values when the salivas were assayed
against each of the GbpB-derived peptides. Significant postin-
fection increases in the FI/IgA antibody values were observed
when the reactivities of these salivas with the QGQ and VAR
peptides were compared with the changes in reactivity when
salivas were tested against BSA. The postinfection increase in
the group salivary antibody activity did not reach significance
with several peptides (SYI, QAA, ANY, and SIG), although
after infection occasional salivas did exhibit apparent increases
with the SYI and SIG peptides. Thus, certain GbpB-derived
peptides apparently induced a mucosal immune response after
infection with GbpB-bearing and -secreting S. mutans.
Comparison of salivary IgA antibody levels following S. mu-
tans infection or mucosal (intranasal) immunization with Gtf.
We investigated the relative expression of salivary IgA anti-
body to Gtf following infection or following intranasal immu-
nization with Gtf delivered in PLGA microparticles. For the
latter condition, the levels of IgA antibody to Gtf were mea-
sured in the salivas of rats 2 weeks after completion of an
immunization regimen consisting of three weekly intranasal
inoculations of S. sobrinus Gtf. Previous studies indicated that
this collection time corresponded to the peak mucosal re-
sponse (36). Figure 6 shows a comparison of the salivary IgA
antibody levels of rats immunized intranasally with the corre-
sponding IgA antibody levels of the infected rats described
above. Mucosal immunization induced a 10-fold-higher level
of salivary IgA antibody to Gtf than infection induced. Inter-
estingly, however, salivas from 4 of the 22 infected rats had IgA
antibody levels within the range observed for the immunized
group.
FIG. 4. Salivary IgA antibody reactivity with Gtf-derived peptides
in combined rat salivas from experiments 1 and 2 (22 rats). The results
are expressed as the median increases in postinfection salivary IgA
antibody activity compared with preinfection salivary IgA antibody
activity for each of the peptides indicated on the abscissa, measured as
the Luminex FI for reaction of salivas with peptide-, Gtf-, or BSA-
coated microspheres, divided by the IgA concentration of the saliva.
The increases for each set of 22 salivas tested with each peptide were
compared by one-way ANOVA with the increases for the same set of
salivas tested with BSA. Peptide reactivities that were meaningfully
elevated above the BSA reactivity are indicated by the black bars,
within which the levels of statistical significance are shown.
FIG. 5. Salivary IgA antibody reactivity with GbpB-derived pep-
tides in combined rat salivas from experiment 1 and two additional
infection experiments (18 rats). The results are expressed as the me-
dian increases in postinfection salivary IgA antibody activity compared
with preinfection salivary IgA antibody activity for each of the peptides
indicated on the abscissa, measured as the Luminex FI for reaction of
salivas with peptide-, GbpB-, or BSA-coated microspheres, divided by
the IgA concentration of the saliva. The increases for each set of 18
salivas tested with each peptide were compared by one-way ANOVA
with the increases for the same set of salivas tested with BSA. Peptide
reactivities that were meaningfully elevated above the BSA reactivity
are indicated by the black bars, within which the levels of statistical
significance are shown.
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DISCUSSION
The results of this study clearly demonstrate that infection of
pathogen-free rats with S. mutans can induce a detectable
mucosal IgA antibody response to at least two streptococcal
proteins that are associated with the ability of this cariogenic
streptococcus to accumulate in the oral biofilm. Similar to the
pattern seen in young children of salivary IgA antibody spec-
ificities following primary exposure to immunogenic levels of S.
mutans infection (25, 26), responses to both glucosyltrans-
ferases and glucan binding protein B were observed in a ma-
jority of rats under the infection conditions used in these ex-
periments. Although the IgA antibody levels covered a wide
range and were, on average, 10-fold less than those that could
be obtained by intranasal immunization with Gtf (Fig. 6) or
GbpB (data not shown) during the same time frame, the re-
sponses following infection were significant and occasionally
fell within the range of the responses arising from immuniza-
tion.
Induction of secretory immunity by oral infection is not
surprising and has often been demonstrated in humans for
many mutans streptococcal antigens, including Gtf (5, 10),
GbpB (25, 34), adhesins (4, 13), and other components (for a
review, see reference 31). Salivary antibody to several of these
components can be detected soon after mutans streptococci
become established in the oral biofilm (34). Much of the ini-
tially detectable salivary IgA antibody to mutans streptococci
in young children is antibody to a relatively small number of
components. Interestingly, the “response” can be quite vari-
able in terms of the degree and the antigen recognized, even
between siblings in the same family who would presumably be
exposed to similar infectious doses from the primary caregiver
(34). This variability is similar to that seen in this animal study
in that there was no significant correlation between antibody to
Gtf and antibody to GbpB among the 22 rats following expo-
sure to a single strain of S. mutans. Thus, the rat experimental
model reflects the individuality of the adaptive immune re-
sponse and may mimic the human experience in this regard.
Identification of the epitopes inducing natural immune re-
sponses to infection would be helpful not only for understand-
ing the dynamics of mucosal immunity to virulence antigens
but also for designing strategies to intervene in pathogen in-
fection. Peptides obtained from several locations within the
glucosyltransferase enzyme were shown to react with salivary
IgA antibody in S. mutans-infected rats. More than 50% of the
infected animals showed a significant increase in responses
reactive with the HDS peptide. This 19-mer peptide is associ-
ated with the beta7 strand element of the putative (beta,
alpha)8 catalytic barrel domain of Gtf (8) and contains a cat-
alytically essential histidine residue (His461 in S. mutans GtfB)
(42). Site-directed mutagenesis of a nearby aspartate (Asp467
in S. mutans GtfB) within the HDS-associated Gtf sequence
altered the water solubility of the glucan synthesized from
sucrose (29). Furthermore, this peptide can induce significant
levels of serum IgG and salivary IgA antibodies reactive with
Gtf after mucosal (intranasal) immunization of Sprague-Daw-
ley rats (37). The “natural” immunogenicity of the epitope(s)
in the HDS sequence may trigger immune responses which can
modify the incorporation of mutans streptococci, an hypothesis
which can now be explored using the rodent model.
Significant salivary IgA antibody reactivity was also associ-
ated with the GLU and GLB peptides in the glucan binding
domain. This reactivity may in part be the result of the repeat-
ing motifs within these sequences (1, 17, 43), potentially in-
creasing both the frequency of their potential immunogenicity
and the subsequent glucan binding within the Gtf molecule.
Experimental immunization with the GLU peptide can give
rise to significant inhibition of Gtf enzymatic activity (39).
Injection of this peptide into a local salivary gland (41) and
intranasal immunization with a chimeric vaccine containing a
larger portion of the glucan binding domain (15) each resulted
in protective immunity to experimental infection with mutans
streptococci. This result was not observed when Pep 16 was
used to immunize rats (7). It is notable that previous studies
showed that there was a significant correlation with adult hu-
man parotid IgA antibody reactive with the GLU peptide and
Gtf from either S. mutans or S. sobrinus (39). Thus, it is not
surprising that infection of rats also gives rise to salivary IgA
antibody reactive with epitopes reflected in this peptide’s se-
quence and that the results further support the use of this
model to explore correlations of natural immune response
characteristics and mutans streptococcal infection.
Salivary IgA antibody from infected rats also showed signif-
icant reactivity with peptides derived from the N terminus of
the GbpB protein. At least three GbpB epitopes capable of
inducing a mucosal immune response following infection were
located in an 80-residue region between residues 52 and 113.
Experimental immunization with at least one peptide in this
region has been shown to give rise to protective immunity (38)
and can induce salivary IgA antibody after mucosal immuni-
zation (27). The epitope(s) associated with the VAR peptide
FIG. 6. Comparison of salivary IgA antibody induction by S. mu-
tans infection or by mucosal immunization with Gtf. Salivary IgA
antibody to Gtf in the collective infection experiments (22 rats) was
compared with antibody reactivity in eight rats which were sham im-
munized intranasally (sham-IN) and 16 rats which were intranasally
immunized with PLGA-Gtf or Gtf and aluminum phosphate (IN). The
results are expressed as the group mean  standard error (SE) of the
Luminex FI of saliva IgA antibody reactivity with Gtf-coated micro-
spheres. FIs of individual rat salivas are indicated by open circles.
preSM, preinfection salivas; postSM, postinfection salivas.
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showed significant reactivity in salivas of more than 70% of the
infected rats. Few animals exhibited a change in the levels of
salivary IgA antibody to the QAA and ANY peptides following
infection. The pattern of salivary IgA antipeptide reactivity in
this rat study is quite similar to the pattern recently observed
for salivas of young children during their initial exposure to
mutans streptococci (26). In the previous study, the levels of
salivary IgA antibody to the VAR and QGQ peptides corre-
lated with the levels of salivary IgA antibody reactive with S.
mutans GbpB, providing evidence that the peptide-reactive
antibody was indeed derived from the mucosal response to
GbpB. The levels of salivary IgA antibody to the QAA and
ANY peptides were unremarkable in the children, although
several children did have elevated levels of antibody to the SIG
peptide. Again, this overall correspondence between human
and rat salivary IgA responses to GbpB epitopes emphasizes
their similarity in mucosal immune recognition. Interestingly,
all responsive GbpB peptides have been shown to induce sig-
nificant levels of antibody following immunization (B. Shen,
W. F. King, M. A. Taubman, and D. J. Smith, presented at the
82nd General Session of the IADR/AADR/CADR, 10 to 14
March 2004; C. E. Smith, W. F. King, M. A. Taubman, and
D. J. Smith, presented at the 83rd General Session of the
IADR/AADR/CADR, 10 to 13 March 2005).
Taken together, the results show that infection alone was
sufficient to induce a variety of antibody specificities to
epitopes on two proteins which are central to the accumulation
of S. mutans in the oral biofilm. The correspondence between
rats and humans of mucosal immune responsiveness to natu-
rally presented Gtf and GbpB epitopes suggests that the rat
may be a useful model to explore and define mucosal responses
that could be expected in humans and, under controlled infec-
tion conditions, be helpful in unraveling relationships between
the host response and oral biofilm development.
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